ResearcherWenzhou Medical UniversityActive in the last 2 years
Haibo Yu
Matched on ORCID iD 0009-0003-0136-4762; OpenAlex author ID A5018973052. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2014: 1 paper · 2015: none · 2016: none · 2017: 3 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 7
- A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer. Last author DOI 10.29271/jcpsp.2024.12.1456↗
- Corrigendum to" Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW190… Last author DOI 10.1016/j.yexmp.2020.104565↗
- MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. Co-author DOI 10.1016/j.yexmp.2019.04.012↗
- The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic… Co-author DOI 10.1016/j.biopha.2017.10.026↗
- Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targe… Last author DOI 10.1016/j.yexmp.2017.05.009↗
- Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation a… First author DOI 10.12659/msm.901292↗
- Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Last author DOI 10.1007/s10147-013-0549-2↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun Xiao · 4 shared papers, 2017–2021 · strength 0.43
- Paper Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of… DOI 10.12659/msm.901292↗
- Paper Corrigendum to" Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and ap… DOI 10.1016/j.yexmp.2020.104565↗
- Paper The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transitio… DOI 10.1016/j.biopha.2017.10.026↗
- Bujian Pan · 4 shared papers, 2017–2021 · strength 0.39
- Paper Corrigendum to" Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and ap… DOI 10.1016/j.yexmp.2020.104565↗
- Paper MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. DOI 10.1016/j.yexmp.2019.04.012↗
- Paper The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transitio… DOI 10.1016/j.biopha.2017.10.026↗
- Shiwei Guan · 1 shared paper, 2024 · strength 0.31
- Quan Lin · 1 shared paper, 2024 · strength 0.31
- Xizhou Lin · 2 shared papers, 2017–2021 · strength 0.21
- Paper Corrigendum to" Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and ap… DOI 10.1016/j.yexmp.2020.104565↗
- Paper The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transitio… DOI 10.1016/j.biopha.2017.10.026↗
- Wu Ji · 2 shared papers, 2017–2019 · strength 0.17
- Jing Cai · 1 shared paper, 2019 · strength 0.10
- Xizhou Lin · 1 shared paper, 2017 · strength 0.07
- Si Guo · 1 shared paper, 2014 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.